Better drug targets are the master key to innovative medicines in areas of unmet medical need. Sequence Bio was founded to discover the true signals of disease and accelerate the discovery of novel drug targets that power life-changing medicines.
It’s a globally important goal we believe is best accomplished in Newfoundland and Labrador.
That’s the story that our CEO Chris Gardner and Chief Strategy Officer Dr. Rick Leach shared with the American Society of Human Genetics - the world’s largest meeting in human genetics.
Sequence Bio was one of a select number of organizations invited to participate in #ASHG21’s Thought Leadership Film Series. Our film explains how our team of local and global experts are using a systems biology approach to identify better drug targets by starting with highly-curated discovery cohorts.
See how Sequence Bio is working with leading pharma and biotech to improve target discovery efficiency with custom cohorts powered by the Newfoundland founder effect.
The ASHG Annual Meeting, produced by the American Society of Human Genetics (ASHG), is the largest human genetics and genomics meeting and exposition in the world. Held in October, it provides a forum for the presentation and discussion of cutting-edge science in all areas of human genetics. Highlights include invited symposia; abstract-driven plenary, platform, and poster sessions; education/trainee workshops; and career opportunities and networking events.
For more information, please visit ASHG.org
VP, Market Development